Experts are worried about tuberculosis again
The deadly disease regained its crown as the world's biggest infectious killer in October 2022


Tuberculosis, commonly abbreviated as TB, may be on its way to becoming a global crisis, according to the United Nations. The deadly disease once again claimed its spot as the number one infectious killer globally in October of 2022, overtaking Covid-19, AFP reported. While progress was being made against the disease, the arrival of Covid in 2020 was a setback that caused cases to swell for the first time in a decade. “We went from what I honestly consider to be unbelievably slow progress, but at least progress, to a reversal," Mel Spigelman, president of the non-profit TB Alliance, told AFP in 2022.
TB is a highly contagious disease that“knows no borders,” Dr. Lucica Ditiu, executive director of the U.N.-hosted organization Stop TB Partnership, told Time. “So long as you breathe, you can still catch TB.” While antibiotics were developed to fight the disease, new strains of drug-resistant TB have evolved, causing higher rates of mortality. Approximately 3.6% of today’s new tuberculosis cases are resistant to multiple TB drugs. “There’s no biological reason that multi-drug-resistant TB can't acquire what it takes to transmit easily,” David Bishai, the director of the school of public health at the University of Hong Kong, told Time. “And so this does represent a pandemic threat.”
To fight the new strains, pharmaceutical company Johnson & Johnson developed a drug called bedaquiline that is effective against drug-resistant TB. The company also opted to not enforce secondary patents on the drug, allowing “current and future generic manufacturers” the ability to “manufacture and sell high-quality generic versions,” as long as the generic versions are “of good quality, medically acceptable,” and are only used in 134 specific low and middle-income countries, according to a J&J press release.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
Why are American conservatives clashing with Pope Leo?
Talking Points Comments on immigration and abortion draw backlash
-
9 haunted hotels where things definitely go bump in the night
The Week Recommends Don’t fear these spirited spots. Embrace them.
-
Saudi comedy fest exposes free speech schism in stand-up
IN THE SPOTLIGHT The decision by some of stand-up’s biggest names to attend a festival in a nation infamous for its censorship has the comedy world picking sides and settling old scores
-
‘Nightmare bacteria’ are rapidly spreading
Under the radar The infections are largely resistant to antibiotics
-
Kissing bug disease has a growing presence in the US
The explainer The disease has yielded a steady stream of cases in the last 10 years
-
Private equity firms might be causing more deaths in hospital ERs
The Explainer Deaths in ERs purchased by private equity firms rose 13%
-
Sloth fever shows no signs of slowing down
The explainer The vector-borne illness is expanding its range
-
A new subtype of diabetes was found and it may require different treatment
Under the radar It is prevalent in Black Africans and Americans
-
How China is battling the chikungunya virus
Under The Radar Thousands of cases of the debilitating disease have been found in the country
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Why the FDA wants to restrict kratom-related products
In the Spotlight The compound is currently sold across the United States